Article
Medicine, General & Internal
Borja Hernandez-Breijo, Claudia M. Brenis, Chamaida Plasencia-Rodriguez, Ana Martinez-Feito, Marta Novella-Navarro, Dora Pascual-Salcedo, Alejandro Balsa
Summary: The study found that TNFi survival did not depend on seropositivity status, but seropositive patients who received concomitant MTX had significantly longer median survival time. Additionally, the co-administration of prednisone in seropositive patients receiving TNFi was highly associated with TNFi discontinuation.
FRONTIERS IN MEDICINE
(2021)
Article
Medicine, General & Internal
Salvatore D'Angelo, Enrico Tirri, Angela Maria Giardino, Marco Mattucci-Cerinic, Lorenzo Dagna, Leonardo Santo, Francesco Ciccia, Bruno Frediani, Marcello Govoni, Francesca Bobbio Pallavicini, Rosa Daniela Grembiale, Andrea Delle Sedie, Rita Mule, Francesco Paolo Cantatore, Rosario Foti, Elisa Gremese, Paola Conigliaro, Fausto Salaffi, Ombretta Viapiana, Alberto Cauli, Roberto Giacomelli, Luisa Arcarese, Giuliana Guggino, Romualdo Russo, Amy Puenpatom, Domenico Capocotta, Francesca Nacci, Maria Grazia Anelli, Valentina Picerno, Corrado Binetti, Florenzo Iannone
Summary: This prospective observational study collected data from rheumatology clinics in Italy and found that golimumab (GLM) as a second anti-TNF drug is effective in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). GLM improved disease activity and quality of life in these patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Immunology
Mathieu Ferrari, Shimobi C. Onuoha, Liliane Fossati-Jimack, Alessandra Nerviani, Pedro L. Alves, Sara Pagani, Cecilia Deantonio, Federico Colombo, Claudio Santoro, Daniele Sblattero, Costantino Pitzalis
Summary: Novel tissue-specific agent BsAb shows improved therapeutic effect by targeting the arthritic synovium, providing better efficacy compared to standard treatment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Gaelle Vial, Celine Lambert, Bruno Pereira, Marion Couderc, Sandrine Malochet-Guinamand, Sylvain Mathieu, Marie Eva Pickering, Martin Soubrier, Anne Tournadre
Summary: This study found that in active RA patients, treatment with TNFi for 1 year was associated with favorable changes in body composition and muscle function compared to other treatment modalities.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Chemistry, Medicinal
Mengshi Tang, Yan Zeng, Weijun Peng, Xi Xie, Yongyu Yang, Biting Ji, Fen Li
Summary: This article reviews the effects of quercetin (QUE) on both articular and extra-articular manifestations of rheumatoid arthritis (RA), suggesting that QUE can inhibit inflammation and bone damage in the joints, as well as provide neuroprotection and cytoprotection.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Article
Immunology
Milena Iwaszko, Joanna Wielinska, Jerzy Swierkot, Katarzyna Kolossa, Renata Sokolik, Bartosz Bugaj, Monika Chaszczewska-Markowska, Slawomir Jeka, Katarzyna Bogunia-Kubik
Summary: The IL-33 gene polymorphisms are closely associated with clinical parameters, disease activity, and response to TNF inhibitor treatment in patients with RA and AS, with the rs16924159 AA genotype potentially linked to higher disease activity and poor treatment response.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Anna Shin, Joo Ho Lee, You-Jung Ha, Yun Jong Lee, Eun Bong Lee, Eun Ha Kang
Summary: This study compared the infectious risk between leflunomide and TNF inhibitors (TNFi), and between tacrolimus and TNFi in rheumatoid arthritis patients receiving methotrexate (MTX). The results showed no significant difference in the risk of serious infections between leflunomide versus TNFi, and between tacrolimus versus TNFi among RA patients receiving background MTX.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2022)
Article
Rheumatology
Elise van Mulligen, Saad Ahmed, Angelique E. A. M. Weel, Johanna M. W. Hazes, Annette H. M. van der Helm-van Mil, Pascal H. P. de Jong
Summary: This study explores the real-world biological survival in rheumatoid arthritis patients, identifying factors influencing biological survival such as RF and ACPA positivity, and the use of csDMARDs. Tailoring treatment based on autoantibody status may be a crucial step towards personalized medicine in RA.
CLINICAL RHEUMATOLOGY
(2021)
Article
Multidisciplinary Sciences
Haroutyun Joulfayan, Tigran Makunts, Ruben Abagyan
Summary: Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects 1% of the global population. The use of TNF inhibitors for RA treatment may lead to adverse events, such as the onset of psoriasis. This study analyzed a large number of safety reports and provided evidence for a significant association between TNF inhibitor use and psoriasis, with varying degrees of association observed among different drugs.
SCIENTIFIC REPORTS
(2023)
Article
Endocrinology & Metabolism
Xiangjiao Yi, Xin Liu, H. Mark Kenney, Rong Duan, Xi Lin, Edward Schwarz, Zhenqiang Yao
Summary: The study evaluated the effects of anti-TNF therapy on osteoporosis in an animal model of RA and found that while it can block the development of erosive arthritis, it only slightly increases vertebral and trabecular bone mass, which may be related to the mechanisms of osteoblast stimulation.
JOURNAL OF BONE AND MINERAL RESEARCH
(2021)
Article
Medicine, General & Internal
Daniela Anghel, Carmen Adella Sirbu, Oana-Georgiana Petrache, Daniela Opris-Belinski, Maria Magdalena Negru, Violeta-Claudia Bojinca, Cristina Florentina Plesa, Florentina Ionita Radu
Summary: Videocapillaroscopy is a simple, non-invasive investigation used to study nailfold capillaries. It is commonly used for patients with Raynaud's phenomenon and systemic sclerosis, but can also be used for patients with suspected microcirculation alterations. The study aimed to identify nailfold videocapillaroscopic abnormalities in rheumatoid arthritis and psoriatic arthritis patients and analyze their correlation with 12 months of anti-TNF-α therapy. The findings showed significant improvements in capillary density, dilated and giant capillaries, elongated capillaries, and angiogenesis after 12 months of treatment, with no avascular areas found.
Article
Rheumatology
Benjamin Sornrung Naovarat, Gloria Salazar, Mariko Ishimori, Francis M. Williams, John D. Reveille
Summary: The study suggests that biological therapy, particularly anti-TNF agents, is safe and well tolerated in HIV-positive rheumatology patients, even over several years.
Article
Biochemistry & Molecular Biology
Tomasz Wysocki, Agnieszka Paradowska-Gorycka
Summary: Rheumatoid arthritis is a common inflammatory arthritis in which tumor necrosis factor plays a key role. However, there is variation in response to TNF-targeting drugs, which may be influenced by genetic factors. The field of pharmacogenomics offers potential for developing novel prognostic tools.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
Christian Dejaco, Thomas Mueller, Omid Zamani, Ulrike Kurtz, Stefan Egger, Johannes Resch-Passini, Anna Totzauer, Babak Yazdani-Biuki, Thomas Schwingenschloegl, Peter Peichl, Angelika Kraus, Gerhard W. Naerr
Summary: This study aimed to analyze real-world evidence on the effects of golimumab treatment on work productivity, daily activity impairment, and health-related quality of life in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Austria. The study found that golimumab treatment significantly improved work productivity, daily activity impairment, and health-related quality of life.
FRONTIERS IN MEDICINE
(2022)
Article
Orthopedics
Edit Vegh, Janos Gaal, Pal Geher, Edina Goemoeri, Attila Kovacs, Laszlo Kovacs, Katalin Nagy, Edit Feketene Posta, Laszlo Tamasi, Edit Toth, Eszter Varga, Andrea Domjan, Zoltan Szekanecz, Gabriella Szucs
Summary: In this Hungarian study, 18% of RA patients were found to have a high risk of RRP. These patients showed differences in various parameters compared to others. RRP was associated with non-response to MTX.
BMC MUSCULOSKELETAL DISORDERS
(2021)
